Breast Cancer | Specialty

The OncLive Breast Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of breast cancer, including those that are triple negative, hormone receptor positive, and/or HER2 positive. This page features news articles, interviews in written and video format, and podcasts that focus on treatment advances and ongoing research in breast cancer.

Dr. Rugo on PI3K and mTOR Inhibitors for Breast Cancer

August 8th 2013

Hope S. Rugo, MD, from the UCSF Helen Diller Family Comprehensive Cancer Center, gives an overview of the development of PI3K and mTOR inhibitors for the treatment of breast cancer.

Tamoxifen Significantly Lowers Risk of Contralateral Breast Cancer in BRCA-Positive Patients

August 6th 2013

Patients with mutations of BRCA1 or BRCA2 who received tamoxifen after their initial diagnosis of breast cancer reduced their chances of developing contralateral or secondary breast cancer by more than half.

Breast Cancer Heterogeneity Confounds Trial of Dual HER2-Targeted Therapy

August 5th 2013

Exploratory analyses by intrinsic subtype showed that HER2-positive breast cancer is molecularly heterogeneous with varying degrees of sensitivity to HER2-targeted therapy.

Dr. Swain on Pregnant Patients With Breast Cancer

August 5th 2013

Sandra Swain, MD, from the Washington Cancer Institute at MedStar Washington Hospital Center and Georgetown University Medical Center, discusses pregnant patients with breast cancer.

Dr. Hershman on Adherence to Longer Hormonal Therapy

August 1st 2013

Dawn L. Hershman, MD, MS, Associate Professor of Medicine and Epidemiology, Leader, Breast Cancer Program, Herbert Irving Comprehensive Cancer Center, Columbia University, discusses the need for adherence with longer hormonal therapy.

Dr. Tripathy on Targeting HER2 in Breast Cancer

July 31st 2013

Debu Tripathy, MD, co-leader, Women's Cancer Program, University of Southern California Norris Comprehensive Cancer Center, discusses targeting HER2 in breast cancer.

Dr. Albain on the 21- and 70- Gene Assays in Breast Cancer

July 26th 2013

Kathy S. Albain, MD, from the Loyola University Chicago and Cardinal Bernardin Cancer Center, discusses the difference between the 21-gene (Oncotype DX) assay and 70-gene (MammaPrint) assay in breast cancer.

Dr. Aft on Identifying Markers for Micrometastatic Disease

July 24th 2013

Rebecca L. Aft, MD, PhD, from the Siteman Cancer Center, discusses the need to identify markers for patients with micrometastatic disease.

BOLERO-3: Everolimus Might Help Patients Overcome Trastuzumab Resistance

July 23rd 2013

Adding the mTOR inhibitor everolimus to conventional therapy slowed the progression of trastuzumab-resistant advanced breast cancer, and in the process, provided clues to the origin of trastuzumab resistance.

Dr. Minetta Liu on CTCs for Prognosis and Prediction

July 23rd 2013

Minetta Liu, MD, Breast Cancer Specialist, Mayo Clinic, Rochester, Minnesota, discusses the use of circulating tumor cells (CTCs) for prognosis and prediction in patients with breast cancer.

Dr. Lehman on Breast Imaging Across Cancer Centers

July 22nd 2013

Constance D. Lehman, MD, PhD, from the Seattle Cancer Care Alliance, discusses breast imaging across various cancer centers.

Adding Paclitaxel to Neratinib Improves Outcomes Versus Monotherapy

July 22nd 2013

Combining paclitaxel with the investigational compound neratinib increased response rates versus neratinib alone in patients with HER2-positive metastatic breast cancer.

Dr. Mittendorf on Peptide Vaccines for Breast Cancer

July 19th 2013

Elizabeth Mittendorf, MD, PhD, from MD Anderson Cancer Center, discusses the use of peptide vaccines for the treatment of breast cancer.

Suzanne A. W. Fuqua, PhD, on the Androgen Receptor

July 18th 2013

Suzanne A. W. Fuqua, PhD, professor of medicine at Baylor College of Medicine, discusses the androgen receptor in breast cancer.

Dr. Seidman Discusses Less Lymph Node Surgery

July 11th 2013

Andrew D. Seidman, MD, from Weill Cornell Cancer Center and Memorial Sloan-Kettering Cancer Center, discusses less surgery for patients with breast cancer.

Retrospective Analysis Confirms Poor Prognosis for Breast Cancer Patients With BRCA1 Mutations

July 11th 2013

Women with breast cancer who are carriers of BRCA1 mutations have increased mortality compared with noncarriers, according to a retrospective study carried out in the Netherlands.

Dr. Garcia on a Trial Analyzing the PARP Inhibitor Veliparib

July 8th 2013

Agustin A. Garcia, MD, from the Keck School of Medicine of the University of Southern California, discusses a phase I trial analyzing the PARP inhibitor veliparib (ABT-888) in patients with breast cancer.

Hypofractionation Emerges as Standard, but Not Yet for Every Patient

July 8th 2013

Recently published clinical trial results support new radiation therapy protocols for many breast cancer survivorsâŽ¯protocols that could greatly improve collective outcome.

Priority Review Granted to Neoadjuvant Breast Cancer Regimen

July 2nd 2013

The FDA has granted priority review to a regimen of pertuzumab, trastuzumab, and docetaxel for the treatment of patients with HER2-positive early-stage breast cancer.

Dr. Budd Discusses Paclitaxel Regimens in Breast Cancer

June 25th 2013

G. Thomas Budd, MD, Medical Oncologist, Taussig Cancer Center at Cleveland Clinic, discusses the background and results of the S0221 trial in breast cancer.